Price T Rowe Associates Inc. MD Sells 986,108 Shares of Applied Therapeutics, Inc. (NASDAQ:APLT)

Price T Rowe Associates Inc. MD lessened its position in Applied Therapeutics, Inc. (NASDAQ:APLT - Free Report) by 96.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 34,763 shares of the company's stock after selling 986,108 shares during the quarter. Price T Rowe Associates Inc. MD's holdings in Applied Therapeutics were worth $30,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Private Advisor Group LLC bought a new position in Applied Therapeutics during the 4th quarter valued at approximately $35,000. SG Americas Securities LLC boosted its stake in shares of Applied Therapeutics by 169.0% in the 4th quarter. SG Americas Securities LLC now owns 40,747 shares of the company's stock worth $35,000 after buying an additional 25,601 shares during the last quarter. Intech Investment Management LLC boosted its stake in shares of Applied Therapeutics by 176.1% in the 4th quarter. Intech Investment Management LLC now owns 52,631 shares of the company's stock worth $45,000 after buying an additional 33,567 shares during the last quarter. Dark Forest Capital Management LP lifted its position in Applied Therapeutics by 54.5% during the fourth quarter. Dark Forest Capital Management LP now owns 53,718 shares of the company's stock valued at $46,000 after purchasing an additional 18,949 shares in the last quarter. Finally, Legal & General Group Plc lifted its position in Applied Therapeutics by 293.9% during the fourth quarter. Legal & General Group Plc now owns 84,018 shares of the company's stock valued at $72,000 after purchasing an additional 62,686 shares in the last quarter. Hedge funds and other institutional investors own 98.31% of the company's stock.

Applied Therapeutics Trading Down 0.0%

Shares of NASDAQ:APLT traded down $0.00 during mid-day trading on Friday, reaching $0.41. The stock had a trading volume of 1,900,676 shares, compared to its average volume of 3,364,237. The company has a market cap of $58.03 million, a P/E ratio of -0.25 and a beta of 2.00. Applied Therapeutics, Inc. has a 1 year low of $0.30 and a 1 year high of $10.62. The business's 50 day moving average price is $0.42 and its 200 day moving average price is $1.60.

Applied Therapeutics (NASDAQ:APLT - Get Free Report) last posted its earnings results on Monday, April 14th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.06). The company had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.61 million. Analysts predict that Applied Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on APLT. Royal Bank of Canada reiterated a "sector perform" rating and set a $1.50 target price on shares of Applied Therapeutics in a research report on Wednesday, May 14th. Wall Street Zen upgraded Applied Therapeutics to a "sell" rating in a research report on Thursday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus target price of $6.10.

About Applied Therapeutics

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.